Navigation Links
Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
Date:3/31/2009

r. Cross continued, "As is the case with mouse macrophages, our in vitro data suggest that human dendritic cells also kill germinating anthrax bacteria. Importantly, we find that the addition of Valortim(R) (1) enhances the ability of human dendritic cells to kill B. anthracis, (2) increases the upregulation of costimulatory immune molecules on human dendritic cells (CD40 and CD83), and (3) allows for an augmented cytokine response, particularly the pro-inflammatory cytokine IL-23 that is known to stimulate memory T cells and the production of IFN-gamma . Additional work is ongoing to better characterize how Valortim(R) enhances the immune response to B. anthracis infection."

David P. Wright, President and Chief Executive Officer of PharmAthene, commented, "We are delighted to continue our collaboration with Drs. Cross and Basu to better characterize these intriguing results. Valortim(R) has demonstrated efficacy in non-clinical studies as well as favorable safety data collected from our Phase I clinical study. We believe that Valortim(R) may have important competitive advantages, including a novel mechanism of action, which, if demonstrated, would make it a strong choice for procurement consideration in the Strategic National Stockpile."

The work reported by Drs. Cross and Basu is supported by the Maryland Industrial Partnerships Program (MIPS). The MIPS program was developed to accelerate the commercialization of technology in Maryland by jointly funding collaborative R&D projects between companies and University System of Maryland faculty.

About Valortim(R)

Valortim(R) is a fully human monoclonal antibody designed to protect against and treat anthrax infection, including inhalational anthrax, the most lethal form of illness in humans caused by the Bacillus anthracis bacterium. The investigational antibody is designed to target a protein component known as
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)...  Ascendant Solutions, Inc. (Pink Sheets: ASDS ) ... subsidiary, Dougherty,s Holdings, has acquired Springtown Drug (" ... Springtown, Texas , just north of ... pharmacy has provided retail prescriptions, healthcare products and gifts ... . The Springtown ...
(Date:8/31/2015)... Pa. , Aug. 31, 2015 The ... reversed statewide since Pennsylvania State ... life-saving drug kits, naloxone. Heroin and opioid ... Pennsylvania , killing more individuals than ... approximately 2,400 Pennsylvanians died from a drug overdose. ...
(Date:8/31/2015)... , Aug. 31, 2015 Regen BioPharma, ... development of a novel means of delivering its ... RGBP-248, to liver tumors utilizing a clinically approved ... overcomes previous hurdles with gene silencing therapeutics in ... delivered throughout the whole body.  By utilizing a ...
Breaking Medicine Technology:Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 2Ascendant Solutions, Inc. Announces Completion of Fifth Pharmacy Acquisition by Its Dougherty's Holdings Subsidiary 3Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 2Departments of Drug & Alcohol Programs and Health Announce Report 289 Pennsylvanian Lives Saved by Naloxone 3Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 2Regen BioPharma, Inc. Develops BORIS Gene Silencing Based Treatment for Unresectable Liver Cancer 3
... June 9 Halozyme Therapeutics,Inc. (Nasdaq: ... products targeting the extracellular matrix, today,announced new ... mellitus program at,the American Diabetes Association,s 68th ... company,s proprietary recombinant human,hyaluronidase enzyme (rHuPH20) with ...
... Pivotal Study Highlighted at Recent Arizona Alzheimer,s ... Consortium Annual Conference in Phoenix -, PHOENIX and ... Health Research Institute today announced that they are,actively enrolling patients ... treatment of Alzheimer,s disease. The study will,evaluate the safety and ...
Cached Medicine Technology:Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 2Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 3Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 4Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability 5Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 2Banner Alzheimer's Institute and Sun Health Research Institute Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimer's Disease 3
(Date:9/1/2015)... ... September 01, 2015 , ... ... borders seldom arise at the most convenient time for everyone involved. These occasions ... help. , Universal Translation Services has real people available to handle ...
(Date:9/1/2015)... ... 2015 , ... Dr. Trace Curry successfully placed one of the first ORBERA™ ... month the FDA has approved two intra-gastric balloons, the ORBERA ™ Managed Weight ... incisionless, reversible, weight loss procedures available to Americans. , Dr. Curry, medical ...
(Date:9/1/2015)... (PRWEB) , ... September 01, 2015 , ... ... to send information about new patients directly from Practice Perfect to FOTO enabling ... data entry. , Steven Presement, President of Practice Perfect, stated ...
(Date:9/1/2015)... ... September 01, 2015 , ... Anthony J. Tantillo, Esq., Attorney from ... his third consecutive year in a row. Through nomination, research and strategic evaluation ... Born in Niagara Falls, New York, Tantillo is a Buffalo State College graduate of ...
(Date:9/1/2015)... ... September 01, 2015 , ... MediNatura™, the exclusive ... workshop for physician assistants (PAs) practicing in orthopedics. The workshop, titled “Treatment of ... by Dr. Erick Salado, an orthopedic surgeon at South Florida Bone and Joint ...
Breaking Medicine News(10 mins):Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 2Health News:Universal Translation Services Provides Quality Translations 24 Hours a Day Including Weekends 3Health News:Dr. Trace Curry Performs First ORBERA™ Intra-gastric Balloon in Ohio at JourneyLite, a New Incisionless Option For The Treatment of Obesity 2Health News:FOTO Announces New Integration Partnership with Practice Perfect 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 2Health News:New Hope for Patients Seeking Treatment of Osteoarthritis Knee Pain 3
... May 19, 2009 (OAKLAND, Calif.) An e-mail intervention ... and physical activity by helping people move more, sit ... Kaiser Permanente Division of Research study in the ... was a randomized controlled trial of the ALIVE (A ...
... LIFE Event raises $500,000 for breast cancer bringing total ... Twenty-eight LPGA pros including World Golf Hall of ... players Angela Stanford, Morgan Pressel, Brittany Lincicome, Helen Alfredsson, ... for the 10th anniversary LIFE (LPGA Pros in the ...
... MEETING, Pa., May 18 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: ... the first quarter ended March 31, 2009. , , ... -- First quarter revenues increased to $39.3 million ... prior year period., -- Gross profit increased to ...
... 18 Gentiva Health Services, Inc. (Nasdaq: GTIV ), ... on May 14, 2009 it received official notification from Nasdaq that ... requirements as set forth in Listing Rule 5605. Under Nasdaq ... regain compliance as follows: , , ...
... Pharmaceuticals, Inc. (Nasdaq: TRBN ) announced today ... 2b study (15002) of TRU-015 for rheumatoid arthritis will ... League Against Rheumatism (EULAR) annual meeting in Copenhagen, Denmark. ... http://www.eular.org/ .(Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ...
... The Quigley Corporation, (Nasdaq: QG L ... , today announced an update on the Company,s ... announcement regarding the unexpected positive finding for its QR-333 ... 11b clinical trial. While the complete statistical results of ...
Cached Medicine News:Health News:Workplace e-mail intervention program helps people sit less and eat better 2Health News:Workplace e-mail intervention program helps people sit less and eat better 3Health News:LIFE 10th Anniversary Event Delivers Big Names and Big Dollars for Breast Cancer Fight 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 2Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 3Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 4Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 5Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 6Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 7Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 8Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 9Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 10Health News:BMP Sunstone Reports First Quarter 2009 Financial Results 11Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 2Health News:Gentiva(R) Health Services Receives Nasdaq Notification Regarding Independent Director Requirement 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 2Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 3Health News:Trubion Pharmaceuticals, Inc. to Present Positive Data From a Phase 2b Re-treatment Study of TRU-015 at the 2009 EULAR Annual Meeting 4Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 2Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 3Health News:The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure 4
... KeraCel Ophthalmic Products are ... formulation of lint-free MEROCEL polyvinyl ... configured to be beneficial to ... being absorbent, and yet firm ...
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
... Merocel Ophthalmic Products provide ... fiber free products for ... safe cleaning of fine ... Merocel material is highly ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: